Arch Capital Group Ltd (ACGL)vsDrugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
ACGL
Arch Capital Group Ltd
$94.46
+1.88%
FINANCIAL SERVICES · Cap: $34.58B
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
$10.53
-0.28%
FINANCIAL SERVICES · Cap: $355.55M
Smart Verdict
WallStSmart Research — data-driven comparison
ACGL leads profitability with a 22.1% profit margin vs 0.0%. ACGL trades at a lower P/E of 8.4x. ACGL earns a higher WallStSmart Score of 81/100 (A-).
ACGL
Exceptional Buy81
out of 100
Grade: A-
DMAA
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 22 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 29.5%
Earnings expanding 38.8% YoY
No standout strengths identified
Areas to Watch
No major concerns identified
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ACGL
The strongest argument for ACGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 22.1% and operating margin at 29.5%. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : DMAA
DMAA has a balanced fundamental profile.
Bear Case : ACGL
No major red flags identified for ACGL, but monitor valuation.
Bear Case : DMAA
The primary concerns for DMAA are Revenue Growth, EPS Growth, Market Cap. A P/E of 55.5x leaves little room for execution misses.
Key Dynamics to Monitor
ACGL profiles as a mature stock while DMAA is a value play — different risk/reward profiles.
ACGL is growing revenue faster at 8.5% — sustainability is the question.
ACGL generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ACGL scores higher overall (81/100 vs 32/100), backed by strong 22.1% margins. Both earn "Exceptional Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arch Capital Group Ltd
FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA
Arch Capital Group Ltd., offers insurance, reinsurance and mortgage products worldwide. The company is headquartered in Pembroke, Bermuda.
Drugs Made In America Acquisition Corp. Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company focused on transforming the U.S. pharmaceutical industry through strategic partnerships with innovative firms dedicated to enhancing domestic drug production and distribution. In response to growing concerns over supply chain vulnerabilities, DMAA aims to facilitate the development of more accessible and cost-effective pharmaceuticals, thereby addressing critical market needs. By investing in technological advancements and fostering collaboration within the healthcare sector, DMAA is positioned to play a pivotal role in revitalizing local manufacturing and improving consumer access to essential medications.
Compare with Other INSURANCE - DIVERSIFIED Stocks
Want to dig deeper into these stocks?